Malignant Neoplasm Progression
149 drugs140,144 FAERS reportsMedDRA PT
GET
/api/v1/reaction/malignant-neoplasm-progressionReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
Drugs reporting Malignant Neoplasm Progression (149)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Afatinib1,68426%
- 2Streptozocin5725%
- 3Gefitinib1,81720%
- 4Zongertinib1218%
- 5Pralatrexate11818%
- 6Ceritinib42618%
- 7Euphorbia Resinifera Resin114%
- 8Rucaparib1,18414%
- 9Tisagenlecleucel59913%
- 10Ramucirumab80013%
- 11Fulvestrant4,11313%
- 12Cellulase113%
- 13Pancreatin113%
- 14Enfortumab77312%
- 15Pembrolizumab11,56212%
- 16Eribulin38110%
- 17Osimertinib3,14210%
- 18Vinorelbine69710%
- 19Nivolumab9,75810%
- 20Dostarlimab20410%
- 21Selpercatinib12610%
- 22Goserelin1,31410%
- 23Tebentafusp5510%
- 24Dextran 70110%
- 25Olaparib2,00810.0%
- 26Belzutifan13410.0%
- 27Pirtobrutinib699.9%
- 28Enzalutamide5,4409.4%
- 29Everolimus4,6409.2%
- 30Ipilimumab3,7178.8%
- 31Ribociclib2,6458.7%
- 32Exemestane1,7958.5%
- 33Trametinib2,0138.5%
- 34Dabrafenib1,7378.4%
- 35Pemetrexed3,0428.3%
- 36Retifanlimab38.1%
- 37Octreotide2,4588.1%
- 38Durvalumab1,4747.9%
- 39Vorasidenib347.8%
- 40Capmatinib1797.7%
- 41Zolbetuximab807.4%
- 42Lenvatinib2,3057.3%
- 43Letrozole4,3897.2%
- 44Erlotinib8897.2%
- 45Cabozantinib3,3447.1%
- 46Relatlimab317.1%
- 47Tisotumab596.9%
- 48Cabazitaxel2356.9%
- 49Ixabepilone706.7%
- 50Elranatamab576.5%
- 51Pazopanib1,6566.2%
- 52Tucatinib4146.2%
- 53Niraparib1,3526.2%
- 54Tremelimumab2325.9%
- 55Dotatate3415.9%
- 56Alpelisib5025.9%
- 57Naldemedine925.8%
- 58Dacomitinib425.7%
- 59Fenbendazole55.6%
- 60Abemaciclib1,0405.6%
- 61Gemcitabine2,8215.5%
- 62Mosunetuzumab455.4%
- 63Interleukin-10195.3%
- 64Interleukin-11195.3%
- 65Interleukin-3195.3%
- 66Interleukin-5195.3%
- 67Duvelisib405.3%
- 68Carboplatin5,9024.8%
- 69Elotuzumab2454.8%
- 70Pentetreotide64.7%
- 71Topotecan3164.7%
- 72Capivasertib1094.6%
- 73Mitotane794.5%
- 74Aluminum Sulfate34.5%
- 75Aluminum Sulfate Tetradecahydrate34.5%
- 76Tamoxifen2574.5%
- 77Temozolomide9104.4%
- 78Paclitaxel4,1604.3%
- 79Capecitabine3,9024.3%
- 80Irinotecan5284.3%
- 81Pamidronate1444.3%
- 82Platinum434.2%
- 83Cisplatin3,1624.1%
- 84Lanreotide3164.1%
- 85Levoleucovorin1484.1%
- 86Docetaxel2,7204.1%
- 87Indium64.1%
- 88Metyrosine33.9%
- 89Talazoparib673.9%
- 90Ripretinib1953.9%
- 91Tafasitamab333.8%
- 92Anastrozole1,3583.8%
- 93Lapatinib5593.6%
- 94Nelarabine343.6%
- 95Toremifene153.6%
- 96Lutetium6323.5%
- 97Cetuximab1,0833.5%
- 98Ifosfamide7173.4%
- 99Imatinib1,4033.4%
- 100Aldesleukin413.4%
- 101Tivozanib523.4%
- 102Flutamide333.4%
- 103Bexarotene433.3%
- 104Lorlatinib2093.2%
- 105Vandetanib573.2%
- 106Polatuzumab Vedotin2873.2%
- 107Romidepsin523.1%
- 108Lisocabtagene Maraleucel232.9%
- 109Dacarbazine2052.8%
- 110Mechlorethamine632.8%
- 111Crotamiton172.8%
- 112Fluorouracil2,0892.8%
- 113Bendamustine7402.8%
- 114Lomustine692.8%
- 115Etoposide1,9942.7%
- 116Dactinomycin592.7%
- 117Ivosidenib522.7%
- 118Carmustine1232.7%
- 119Larotrectinib232.7%
- 120Acalabrutinib3062.7%
- 121Asciminib772.6%
- 122Repotrectinib62.6%
- 123Megestrol962.5%
- 124Triptorelin1402.5%
- 125Vorinostat532.5%
- 126Palbociclib2,3242.5%
- 127Doxorubicin2,2672.4%
- 128Epcoritamab282.4%
- 129Ibritumomab Tiuxetan362.4%
- 130Encorafenib2252.4%
- 131Tetraxetan2902.3%
- 132Vipivotide Tetraxetan2902.3%
- 133Thalidomide8522.3%
- 134Crizotinib2932.3%
- 135Binimetinib1762.3%
- 136Dasatinib8432.3%
- 137Oxaliplatin1,6212.3%
- 138Brentuximab Vedotin2232.2%
- 139Metyrapone212.2%
- 140Trifluridine2382.2%
- 141Elacestrant1532.2%
- 142Sonidegib322.2%
- 143Tipiracil2272.2%
- 144Chlorambucil832.1%
- 145Bevacizumab2,6932.1%
- 146Diazoxide222.1%
- 147Abiraterone7691.9%
- 148Mitomycin571.8%
- 149Brigatinib83—
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Disease Progression103 shared · 0.37
- Neutropenia68 shared · 0.22
- Decreased Appetite96 shared · 0.22
- Febrile Neutropenia52 shared · 0.20
- Anaemia94 shared · 0.18
- Platelet Count Decreased42 shared · 0.16
- Thrombocytopenia52 shared · 0.16
- Neuropathy Peripheral33 shared · 0.15
- Death134 shared · 0.14
- Neoplasm Progression22 shared · 0.13
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.